Company news

Genprex, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Genprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive

October 23, 2024

Genprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

October 14, 2024

Genprex Announces Formation of Mesothelioma Clinical Advisory Board

September 18, 2024

Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes

September 3, 2024

Genprex Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer

August 13, 2024

Genprex Granted Patent in Singapore for Reqorsa® Gene Therapy with PD-1 Antibodies to Treat Cancers

August 12, 2024

Genprex to Present at the 2024 BIO International Convention

May 29, 2024

Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

May 13, 2024

Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors

May 12, 2024

Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner

May 7, 2024

Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

April 2, 2024

Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

March 18, 2024

Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers

March 11, 2024

Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators

February 6, 2024

Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer

February 4, 2024

Genprex Announces 1-for-40 Reverse Stock Split Effective February 2, 2024

January 30, 2024

Genprex Provides Business Update and Outlook for 2024

January 4, 2024

Genprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation for Immunogene Therapy for Treatment of SCLC

September 20, 2023

Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs

August 21, 2023

Genprex Granted FDA Orphan Drug Designation (ODD) for REQORSA® Immunogene Therapy for the Treatment of Small Cell Lung Cancer

August 9, 2023

Genprex Announces $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

July 18, 2023

Gene Therapy Company Genprex, Inc. (NASDAQ: GNPX) Receives Fast Track Designation From The FDA For Its Small Cell Lung Cancer Drug Candidate

July 10, 2023

Genprex Granted Chinese Patent for REQORSA® Immunogene Therapy in Combination with PD-1 Antibodies to Treat Cancers

July 4, 2023

Genprex Receives U.S. FDA Fast Track Designation for REQORSA® Immunogene Therapy in Combination with Tecentriq® for the Treatment of Small Cell Lung Cancer

June 27, 2023

Genprex (NASDAQ: GNPX) Releases New Patient Video Interview Describing Positive Experience In Clinical Trial

June 1, 2023

Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Expansion Portion of Acclaim-1 Clinical Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer

May 29, 2023

Genprex, Inc. Announces $4 Million Registered Direct Offering With a Single, Healthcare-Focused Institutional Investor

February 26, 2023

Genprex Announces Groundbreaking Data from Non-Human Primate Study Evaluating Novel Gene Therapy to Treat Type 1 Diabetes at 16th Annual International Conference on Advanced Technologies & Treatment for Diabetes 2023

February 22, 2023

Genprex Signs Exclusive License to Additional Diabetes Technology with the University of Pittsburgh

January 4, 2023

Genprex Announces Selection of Preclinical Data for Oral Presentation at 16th International Conference on Advanced Technologies & Treatments for Diabetes

January 3, 2023

Genprex Strengthens Diabetes Gene Therapy Program with License of Additional Technology from University of Pittsburgh

December 14, 2022

Genprex Receives Safety Review Committee Approval to Proceed to Final Cohort in Acclaim-1 Phase 1 Dose Escalation Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer

December 13, 2022

Genprex Announces U.S. Patent for REQORSA™ Immunogene Therapy in Combination with Immune Checkpoint Inhibitors to Treat Cancers

August 15, 2022

Genprex Announces Safety Review Committee Approves Dose Escalation in Acclaim-1 Phase 1/2 Trial of REQORSA™ in Combination with Tagrisso® in Non-Small Cell Lung Cancer

August 14, 2022

Genprex Issues Shareholder Letter and Provides 2022 Corporate Update

May 4, 2022

Genprex Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial of REQORSA™ Immunogene Therapy in Combination With Keytruda® to Treat Non-Small Cell Lung Cancer

March 30, 2022

Genprex Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer

March 1, 2022

Genprex to Accelerate Opening of Acclaim-1 Clinical Trial Sites for REQORSA™ Systemic Gene Therapy in Non-Small Cell Lung Cancer

January 9, 2022

Genprex Expands Gene Therapy Oncology Pipeline to Include Small Cell Lung Cancer

January 3, 2022

Genprex Receives U.S. FDA Fast Track Designation for REQORSA™ Immunogene Therapy in Combination With Keytruda® for the Treatment of Non-Small Cell Lung Cancer

January 2, 2022

Genprex Strengthens Management Team with Appointments of Industry Leaders Mark S. Berger, M.D. as Chief Medical Officer and Hemant Kumar, Ph.D. as Chief Manufacturing and Technology Officer

September 27, 2021

Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer Following FDA Review

June 22, 2021

Genprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung Cancer

May 5, 2021

Genprex Announces Centralized Institutional Review Board Approval for Acclaim-1 Clinical Trial in Non-Small Cell Lung Cancer

May 4, 2021

Genprex Initiates Site Recruitment for Acclaim-2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer

May 3, 2021

Genprex to Receive Inaugural “License of the Year” Award from University of Pittsburgh Innovation Institute in Recognition of Advances Made with Gene Therapy Program in Diabetes

April 19, 2021

Genprex Announces Preclinical Data for TUSC2 Immunogene Therapy in Non-Small Cell Lung Cancer to Be Featured in Two Presentations at the 2021 American Association for Cancer Research Annual Meeting

March 29, 2021

Genprex, Inc. Announces $25 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules, Without Warrants

February 8, 2021

Genprex Announces Formation of Clinical Advisory Board

February 7, 2021

Genprex Achieves Major Manufacturing Milestone for REQORSA™ Immunogene Therapy for Upcoming Trials to Treat Non-Small Cell Lung Cancer

January 12, 2021

← Newer news releases · Older news releases →

Decks

The 5 newest of 26 decks. Every deck is listed under its year.